Valneva (VLA) investor relations material

Company overview and business model

• Incorporated in France, operates as a foreign private issuer under U.S. securities laws.

• Engaged in vaccine development, with a pipeline including Lyme disease and chikungunya vaccine candidates.

• Collaborates with partners such as Pfizer for regulatory and commercialization activities.

Financial performance and metrics

• Reference to consolidated financial statements and management's assessment of internal controls, with adverse opinion on effectiveness of internal control over financial reporting.

• 189,771,237 ordinary shares outstanding as of May 31, 2026, after recent private placement.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling securityholders, except for up to €47 million if ABSA Warrants are exercised for cash.

• Proceeds from warrant exercises intended for manufacturing, commercialization, R&D, working capital, and general corporate purposes.